PaxMedica Receives Emergency Request For IV Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
PaxMedica Receives Emergency Request For IV Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
PaxMedica 收到非洲卫生部的静脉注射舒拉明的紧急申请，用于治疗致命的昏睡病
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations
As previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug
用于治疗最严重的非洲昏睡病的药物的紧急短缺，使受影响的国家迫切需要直接进入全球药品市场
正如先前报道的那样，PaxMedica 最近执行了 PAX-101（一种静脉注射形式的舒拉明）的最终注册和验证批次，为未来作为孤儿指定药物提交保密协议做准备
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for...
纽约塔里敦，2024年4月16日（GLOBE NEWSWIRE）——通过IBN—...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。